Despite treatment advancements with the introduction of HDMTX and rituximab, up to half of patients will have disease relapse, and 10%–15% may have primary refractory disease.
Bowel side effects do not differ between patients with localized prostate cancer who receive external beam radiation therapy using protons vs photons, investigators reported in a late-breaking ...
The researchers assessed TROP2 expression in 19 patient samples and found that 52% had high TROP2 expression (H-score ≥100; mean 123.6±90; range, 0-248). A post hoc analysis showed that OS positively ...
Paltusotine reduced the frequency and severity of flushing, the frequency and urgency of bowel movements, and the severity of abdominal pain. Paltusotine can alleviate symptoms of carcinoid syndrome ...
While all respondents were primarily concerned about the expected duration of treatment response and treatment impact on patients’ quality of life, other priorities differed. Shared decision-making ...
Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH ...
Enfortumab vedotin may be a treatment option for patients with advanced head and neck cancer that is not amenable to definitive local therapy, researchers say. They reported phase 2 results with ...
Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.